<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20170413033408N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-06-11</date_registration>
      <primary_sponsor>Gorgan University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effect of drug combination in lower back anesthesia on duration of effect and changes in heart rate and blood pressure in patients undergoing orthopedic surgery with lower limb fractures</public_title>
      <acronym></acronym>
      <scientific_title>Comparison the effect of combined of (bupivacaine + magnesium sulfate)  with combined (pethidine + magnesium sulfate) and sole pethidine in spinal anesthesia on effect of duration and  hemodynamic changes in patients under  Lower Limb orthopedic surgery</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-08-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>120</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/47154</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: After selecting the participants who have the conditions to enter the study, using the random blocks method, these people will be assigned to four groups A, B, C, D.
According to the sample size of 30 in the groups, all four blocks of letters A, B, C and D are considered and thirty blocks will be randomly selected; In a random process, a sequence of one hundred and twenty letters A, B, C, D will be created, then this sequence will be numbered from one to 120 numbers. Numbers one to 120 will be placed in a bag, and the researcher will randomly select one of the numbers for each eligible person in the present study, based on the selected number in one of the letters A, B, C, D (respectively to Combination groups (Bupivacaine + Magnesium Sulfate), Combination ( Pethdine + Magnesium Sulfate), Pethdine and Bupivacaine will be done, Blinding description: In this study, in order to perform the method of blinding the patient, the statistical evaluator and analyst will not be aware of the type of groups.</study_design>
      <phase>3</phase>
      <hc_freetext>Lower Limb fracture.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Group A patients will receive Intrathecal magnesium sulfate with 100 mg bupivacaine at a dose of 10 mg. Intervention 2: Intervention group: Group B will be patients receiving 100 mg of Intrathecal magnesium sulfate with pethidine at a dose of 1 mg / kg . Intervention 3: Intervention group: group C Petdin 1 mg / kg will be injected into the spinal cord. Intervention 4: Control group:  Group D Bupivacaine will be injected Intrathecal at a dose of 10 mg.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Information on the main outcome

When:
Since 2021

To whom:
Researchers working in academic institutions

Conditions:
No manipulation, mentioning the data reference

Where to obtain:
Seyed Babak Mojaver Aghili, drbabaka35@gmail.com, Golestan University of Medical Sciences, Deputy of Research and Technology, Gorgan, Golestan, Iran, Gorgan, 4 km, Sari,

How to obtain:
sending an email, complete the personal and professional characteristics with documentation

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>dr Babak Mojaver Aghilli</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Golestan University of Medical Sciences.School of Medicine, Department of Anesthesiology, Gorgan, Shastkola road</address>
        <city>Gorgan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4917763681</zip>
        <telephone>+98 17 3115 3566</telephone>
        <email>drbabaka35@gmail.com</email>
        <affiliation>Gorgan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Seyed babak Mojaveraghili</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Medical school, anesthesia group, Gorgan - Sari 4th kilometers</address>
        <city>Gorgan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>491776381</zip>
        <telephone>+98 17 3115 2566</telephone>
        <email>dr.mojaveraghili@goums.ac.ir</email>
        <affiliation>Gorgan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patient with lower limb fracture candidate for orthopedic surgery which can be performed under spinal anesthesia 
Signing a consent form
Class 1 or 2 of the physical condition of the American Anesthesia Association  ASA
Age range 18-60 years
Elective surgery</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>High intracranial pressure
Infection in site of injection
Impossible of proper position
History of allergy with bupivacaine or pethidine</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M89.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Disorder of bone, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Group A patients will receive Intrathecal magnesium sulfate with 100 mg bupivacaine at a dose of 10 mg.</i_keyword>
      <i_keyword>Intervention group: Group B will be patients receiving 100 mg of Intrathecal magnesium sulfate with pethidine at a dose of 1 mg / kg .</i_keyword>
      <i_keyword>Intervention group: group C Petdin 1 mg / kg will be injected into the spinal cord</i_keyword>
      <i_keyword>Control group:  Group D Bupivacaine will be injected Intrathecal at a dose of 10 mg.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The duration of the anesthetic effect. Timepoint: The duration of anesthesia will be recorded every minute immediately after intravenous injection until the onset of sensory block and every 5 minutes until sensory level stabilization. Method of measurement: Using a blunt needle and register in the checklist.</prim_outcome>
      <prim_outcome>Hemodynamic change. Timepoint: Hemodynamic changes in the operating room will be measured every 5 minutes until the end of the first 30 minutes, then every 15 minutes until the end of surgery. The recovery room will record every 15 minutes until recovery criteria are met. Method of measurement: Hemodynamic criteria (heart rate, systolic, diastolic, and mean arterial blood pressure (MABP), arterial oxygen saturation) of the patient will be measured by Saadat monitoring.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Gorgan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-03-18</approval_date>
        <contact_name>Golestan University of Medical Sciences Ethics Committee</contact_name>
        <contact_address>Gorgan-sari road 4th kilometer,Golestan University of Medical Science Gorgan Golestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
